ARCHIVES

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

Preliminary Study Results Show DES In Utero Exposure May Not Be Threat Originally Feared

February 17, 1978

Mass. Requires Coverage of Routine Patient Care In Clinical Trials

September 6, 2002

Conversation With The Cancer Letter: Seffrin To Retire After Restructuring ACS

January 24, 2014

Preliminary estimates based on NLST results: Year Of Life Saved Could Cost $38,000

July 1, 2011

NCI Programs: Institute Partners With Two Groups On Psychosocial Issues

May 16, 1997

NCI Rethinks Cancer Center Grants

March 14, 2014